Journal article
Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.
Abstract
PURPOSE: This phase II study was designed to assess the effects of mitoxantrone with prednisone in patients with metastatic prostate cancer who had progressed on hormonal therapy. The methods of assessment included quality-of-life analyses, pain indices, analgesic scores, and the National Prostatic Cancer Project (NPCP) criteria.
PATIENTS AND METHODS: Patients received mitoxantrone 12 mg/m2 intravenously every 3 weeks plus prednisone 10 mg …
Authors
Moore MJ; Osoba D; Murphy K; Tannock IF; Armitage A; Findlay B; Coppin C; Neville A; Venner P; Wilson J
Journal
Journal of Clinical Oncology, Vol. 12, No. 4, pp. 689–694
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
April 1994
DOI
10.1200/jco.1994.12.4.689
ISSN
0732-183X